BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

Butler University's plans to renovate and expand Clowes Memorial Hall, including the addition of a ballroom space, aim to create an arts hub in midtown Indianapolis while preserving the building's ...

Ocadusertib is under clinical development by Eli Lilly and Co and currently in Phase II for Rheumatoid ... indication benchmark for progressing into Phase III. GlobalData’s report assesses how ...

Lepodisiran sodium is under clinical development by Eli Lilly and Co and currently in Phase III for Atherosclerosis. According to GlobalData, Phase III drugs for Atherosclerosis have a 24% phase ...